914 patients. One trial. The FDA's August 25 approval of zanidatamab ends more than a decade in which trastuzumab was the only first-line HER2 option for advanced stomach cancer.
The HERIZON-GEA-01 trial cut the risk of death by 28% and extended median survival past 26 months, against a standard set more than fifteen years ago.
Zanidatamab was first developed by Zymeworks and is now advanced by Jazz and BeOne Medicines under license, pairing with and without BeOne's PD-1 inhibitor tislelizumab.
The decision matters less as a single label expansion and more as a reset of how HER2-positive disease is treated from the first infusion.
What the trial actually showed
The HERIZON-GEA-01 study ran 914 previously untreated patients with HER2-positive gastroesophageal adenocarcinoma across roughly 300 sites in more than 30 countries. Human epidermal growth factor receptor 2 (HER2) drives about one in five of these tumors, a slice of the fifth most common cancer worldwide where outcomes have stayed poor for fifteen years. Patients were split three ways: trastuzumab with chemotherapy, zanidatamab with chemotherapy, or zanidatamab with the PD-1 inhibitor tislelizumab and chemotherapy.
Both zanidatamab arms beat the trastuzumab control on the two co-primary endpoints. Median progression-free survival (PFS) reached 12.4 months against 8.1 months, a hazard ratio (HR) of 0.63. Median overall survival (OS) reached 26.4 months against 19.2 months, a 28% lower risk of death and the longest median OS reported in a Phase 3 trial in this setting. The tislelizumab combination carried the survival benefit; the doublet without it showed the PFS gain but not a statistically separate OS result at the interim look.
Progression-free survival gain
Against 8.1 months on trastuzumab-based therapy in HERIZON-GEA-01 (HR 0.63). · Pharmacy Times, 2026
Survival advantage vs trastuzumab
Versus 19.2 months; 28% lower risk of death (HR 0.72). · U.S. FDA, 2026
Addressable patient slice
The share of the fifth most common cancer worldwide that expresses HER2. · Jazz Pharmaceuticals, 2026
Safety signal
Grade 3 in 24% and grade 4 in 2.1% of patients in clinical studies. · PR Newswire, 2026
Why a bispecific, and why now
Zanidatamab binds two distinct sites on HER2, forcing internalization and thinning receptor density on the tumor surface. That dual binding is the mechanism behind the name: a bispecific antibody aimed at one target, not a chemotherapy and not a conjugated payload. Trastuzumab, the incumbent, has anchored first-line HER2 therapy since the ToGA trial set the standard in 2010. For fifteen years the open question was not whether HER2 mattered but whether any agent would displace it. This approval is the first to do so in the front line.
Ziihera is now the first and only bispecific HER2-targeted antibody combined with a PD-1 inhibitor and chemotherapy approved for all HER2-positive advanced GEA patients, regardless of PD-L1 status, establishing a new standard of care in first-line treatment.— Rob Iannone, MD, executive vice president and chief medical officer, Jazz Pharmaceuticals
Ziihera against the field
The competitive frame is not trastuzumab alone. AstraZeneca and Daiichi Sankyo's Enhertu, an antibody-drug conjugate, owns HER2 breast cancer and is advancing into gastric indications. The two are less head-to-head rivals than adjacent bets on the same target across different organs and treatment lines, and zanidatamab's bispecific design engages HER2 in a way neither trastuzumab nor Enhertu does.
| Parameter | Ziihera | Trastuzumab | Enhertu |
|---|---|---|---|
| First-line GEA status | ✔ Approved Aug 2026 | ✔ Standard since 2010 | ◐ In gastric studies |
| Mechanism | Bispecific HER2 | Monoclonal HER2 | Antibody-drug conjugate |
| PD-1 combo option | ✔ Tislelizumab | ✗ | ✗ |
| Lead setting | 1L advanced GEA | 1L GEA | Breast, gastric studies |
The commercial math
Zanidatamab was first developed by Zymeworks and is now advanced by Jazz and BeOne Medicines under license agreements, with the two approved regimens pairing it with and without BeOne's PD-1 inhibitor tislelizumab. Two companion diagnostics, the PATHWAY anti-HER2/neu (4B5) antibody and the VENTANA HER2 Dual ISH probe, were approved alongside the drug, tying uptake to broader HER2 testing at diagnosis.
Safety and the testing bottleneck
The label is not a free pass. Ziihera carries a boxed warning for severe diarrhea, including life-threatening cases, and the prescribing information calls for antidiarrheal prophylaxis in the first cycle when combined with chemotherapy. Serious adverse reactions occurred in 49% of patients in HERIZON-GEA-01, a tolerance profile that will steer frailer patients back toward trastuzumab unless the survival gap widens in practice.
Uptake also rests on diagnostics. The approval bundled two companion tests, the PATHWAY anti-HER2/neu (4B5) antibody and the VENTANA HER2 Dual ISH probe, to flag eligible patients. For fifteen years HER2 testing at diagnosis has been uneven outside major centers, and a front-line standard only helps patients who are actually screened. The dependency is structural: the drug's addressable market is capped by how broadly labs run the assay.
That makes the near-term story as much about infrastructure as chemistry. A bispecific that beats a decade-old standard is necessary but not sufficient; payers, pathology labs, and community oncologists have to move in step for the label to translate into volume.
Can Ziihera hold the first line as Enhertu moves into gastric cancer?
Probability: 55%. The survival and PFS margins are large, the label spans PD-L1 status, and no competing front-line bispecific exists today.
✅ Arguments for
A PD-L1-agnostic label captures the full HER2-positive population, not a biomarker subset.
Confirmation criteria: Enhertu's gastric first-line data reads later than Ziihera's launch, leaving a window for uptake.
❌ Arguments against
Enhertu's breast dominance and ADC payload give it a distinct, hard-to-copy profile if gastric data hold.
Disconfirmation criteria: A front-line Enhertu gastric win with similar survival would split the standard.
Second interim OS analysis for the zanidatamab-chemotherapy doublet, expected by end of September.
Enhertu's gastric first-line dataset and any head-to-head design.
Early-stage gastric trials, where no HER2 therapy is approved today.
Uptake of the two companion diagnostics as a proxy for testing volume.
Development scenarios
🟢 Optimistic scenario (30%)
Implications: Zanidatamab becomes a core Jazz franchise and Zymeworks earns ongoing royalties on a widely adopted first-line standard.
🟡 Base-case scenario (50%)
Implications: Ziihera becomes a durable franchise pillar but not a monopoly in HER2 disease.
🔴 Pessimistic scenario (20%)
Implications: Ziihera settles as a niche first-line option rather than the category standard.